Caseware UK (AP4) 2025.0.111 2025.0.111 2025-11-30No description of principal activityfalsefalse22024-12-012truetrueThe members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006. 07446850 2024-12-01 2025-11-30 07446850 2023-12-01 2024-11-30 07446850 2025-11-30 07446850 2024-11-30 07446850 c:Director1 2024-12-01 2025-11-30 07446850 c:RegisteredOffice 2024-12-01 2025-11-30 07446850 d:MotorVehicles 2024-12-01 2025-11-30 07446850 d:MotorVehicles 2025-11-30 07446850 d:MotorVehicles 2024-11-30 07446850 d:MotorVehicles d:OwnedOrFreeholdAssets 2024-12-01 2025-11-30 07446850 d:ComputerEquipment 2024-12-01 2025-11-30 07446850 d:ComputerEquipment 2025-11-30 07446850 d:ComputerEquipment 2024-11-30 07446850 d:ComputerEquipment d:OwnedOrFreeholdAssets 2024-12-01 2025-11-30 07446850 d:OwnedOrFreeholdAssets 2024-12-01 2025-11-30 07446850 d:CurrentFinancialInstruments 2025-11-30 07446850 d:CurrentFinancialInstruments 2024-11-30 07446850 d:CurrentFinancialInstruments d:WithinOneYear 2025-11-30 07446850 d:CurrentFinancialInstruments d:WithinOneYear 2024-11-30 07446850 d:ShareCapital 2025-11-30 07446850 d:ShareCapital 2024-11-30 07446850 d:RetainedEarningsAccumulatedLosses 2025-11-30 07446850 d:RetainedEarningsAccumulatedLosses 2024-11-30 07446850 c:OrdinaryShareClass1 2024-12-01 2025-11-30 07446850 c:OrdinaryShareClass1 2025-11-30 07446850 c:OrdinaryShareClass1 2024-11-30 07446850 c:FRS102 2024-12-01 2025-11-30 07446850 c:AuditExempt-NoAccountantsReport 2024-12-01 2025-11-30 07446850 c:FullAccounts 2024-12-01 2025-11-30 07446850 c:PrivateLimitedCompanyLtd 2024-12-01 2025-11-30 07446850 6 2024-12-01 2025-11-30 07446850 15 2024-12-01 2025-11-30 07446850 16 2024-12-01 2025-11-30 07446850 17 2024-12-01 2025-11-30 07446850 19 2024-12-01 2025-11-30 07446850 20 2024-12-01 2025-11-30 07446850 d:AcceleratedTaxDepreciationDeferredTax 2025-11-30 07446850 d:AcceleratedTaxDepreciationDeferredTax 2024-11-30 07446850 d:OtherDeferredTax 2025-11-30 07446850 d:OtherDeferredTax 2024-11-30 07446850 e:PoundSterling 2024-12-01 2025-11-30 xbrli:shares iso4217:GBP xbrli:pure
Registered number: 07446850










DR MANISH RAVAL LTD
UNAUDITED
FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 NOVEMBER 2025




















 
DR MANISH RAVAL LTD
 
 
Company Information


Director
Dr M Raval 




Registered number
07446850



Registered office
3rd Floor
12 Gough Square

London

EC4A 3DW





 
DR MANISH RAVAL LTD
Registered number: 07446850

Balance sheet
As at 30 November 2025

2025
2024
Note
£
£

Fixed assets
  

Tangible assets
 4 
229
9,496

Investments
 5 
1,594,892
1,366,717

  
1,595,121
1,376,213

Current assets
  

Debtors: amounts falling due within one year
 6 
38,603
29,967

Cash at bank and in hand
  
243,696
212,030

  
282,299
241,997

Creditors: amounts falling due within one year
 7 
(107,375)
(93,205)

Net current assets
  
 
 
174,924
 
 
148,792

Total assets less current liabilities
  
1,770,045
1,525,005

Provisions for liabilities
  

Deferred tax
 8 
(56,282)
(47,356)

  
 
 
(56,282)
 
 
(47,356)

Net assets
  
1,713,763
1,477,649


Capital and reserves
  

Called up share capital 
 9 
200
200

Profit and loss account
  
1,713,563
1,477,449

  
1,713,763
1,477,649


The director considers that the Company is entitled to exemption from audit under section 477 of the Companies Act 2006 and members have not required the Company to obtain an audit for the year in question in accordance with section 476 of the Companies Act 2006.

The director acknowledges his responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

The financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime and in accordance with the provisions of FRS 102 Section 1A - small entities.

The financial statements have been delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The Company has opted not to file the statement of comprehensive income in accordance with provisions applicable to companies subject to the small companies' regime.


 
Page 1

 
DR MANISH RAVAL LTD
Registered number: 07446850
    
Balance sheet (continued)
As at 30 November 2025


The financial statements were approved and authorised for issue by the board and were signed on its behalf on 27 August 2026.




Dr M Raval
Director

The notes on pages 3 to 9 form part of these financial statements.

Page 2

 
DR MANISH RAVAL LTD
 
 
 
Notes to the financial statements
For the year ended 30 November 2025

1.


General information

Dr Manish Raval Ltd is a private company limited by shares incorporated in the United Kingdom and registered in England and Wales. The company's registered office is 3rd Floor, 12 Gough Square, London, EC4A 3DW.

The principal activity for the company during the year was the provision of consultant anaesthetic services.

2.Accounting policies

 
2.1

Basis of preparation of financial statements

The financial statements have been prepared under the historical cost convention unless otherwise specified within these accounting policies and in accordance with Financial Reporting Standard 102, the Financial Reporting Standard applicable in the UK and the Republic of Ireland and the Companies Act 2006. The disclosure requirements of Section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

The preparation of financial statements in compliance with FRS 102 requires the use of certain critical accounting estimates. It also requires management to exercise judgment in applying the Company's accounting policies.

The financial statements are prepared in sterling, which is the functional currency of the company. Monetary amounts in these financial statements are rounded to the nearest £.

The following principal accounting policies have been applied:

  
2.2

Turnover

Turnover comprises revenue receivable by the company in respect of services supplied during the year. Commissions payable in respect of referrals given are shown separately within administration expenses.

 
2.3

Tangible fixed assets

Tangible fixed assets under the cost model are stated at historical cost less accumulated depreciation and any accumulated impairment losses. Historical cost includes expenditure that is directly attributable to bringing the asset to the location and condition necessary for it to be capable of operating in the manner intended by management.

Depreciation is charged so as to allocate the cost of assets less their residual value over their estimated useful lives, using the straight-line method.

Depreciation is provided on the following basis:

Motor vehicles
-
20%
Computer equipment
-
33%

The assets' residual values, useful lives and depreciation methods are reviewed, and adjusted prospectively if appropriate, or if there is an indication of a significant change since the last reporting date.

Gains and losses on disposals are determined by comparing the proceeds with the carrying amount and are recognised in profit or loss.

Page 3

 
DR MANISH RAVAL LTD
 
 
 
Notes to the financial statements
For the year ended 30 November 2025

2.Accounting policies (continued)

 
2.4

Valuation of investments

Investments in unlisted Company shares, whose market value can be reliably determined, are remeasured to market value at each balance sheet date. Gains and losses on remeasurement are recognised in the Statement of comprehensive income for the period. Where market value cannot be reliably determined, such investments are stated at historic cost less impairment.

Investments in listed company shares are remeasured to market value at each balance sheet date. Gains and losses on remeasurement are recognised in profit or loss for the period.

 
2.5

Debtors

Short-term debtors are measured at transaction price, less any impairment. Loans receivable are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method, less any impairment.

 
2.6

Cash and cash equivalents

Cash is represented by cash in hand and deposits with financial institutions repayable without penalty on notice of not more than 24 hours. Cash equivalents are highly liquid investments that mature in no more than three months from the date of acquisition and that are readily convertible to known amounts of cash with insignificant risk of change in value.

 
2.7

Financial instruments

The Company has elected to apply the provisions of Section 11 “Basic Financial Instruments” of FRS 102 to all of its financial instruments.

Financial instruments are recognised in the Company's Balance sheet when the Company becomes party to the contractual provisions of the instrument.

Basic financial assets

Basic financial assets, which include trade and other debtors, cash and bank balances, are initially measured at their transaction price (adjusted for transaction costs except in the initial measurement of financial assets that are subsequently measured at fair value through profit and loss) and are subsequently carried at their amortised cost using the effective interest method, less any provision for impairment, unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest.

Discounting is omitted where the effect of discounting is immaterial. The Company's cash and cash equivalents, trade and most other debtors due with the operating cycle fall into this category of financial instruments.

Other financial assets

Other financial assets, which includes investments in equity instruments which are not classified as subsidiaries, associates or joint ventures, are initially measured at fair value, which is normally the recognised transaction price. Such assets are subsequently measured at fair value with the changes in fair value being recognised in the profit or loss. Where other financial assets are not publicly traded, hence their fair value cannot be measured reliably, they are measured at cost less impairment.

Page 4

 
DR MANISH RAVAL LTD
 
 
 
Notes to the financial statements
For the year ended 30 November 2025

2.Accounting policies (continued)


2.7
Financial instruments (continued)

Impairment of financial assets

At the end of each reporting period financial assets measured at amortised cost are assessed for objective evidence of impairment. If an asset is impaired the impairment loss is the difference between the carrying amount and the present value of the estimated cash flows discounted at the asset’s original effective interest rate. The impairment loss is recognised in profit or loss. 

Financial assets are impaired when events, subsequent to their initial recognition, indicate the estimated future cash flows derived from the financial asset(s) have been adversely impacted. The impairment loss will be the difference between the current carrying amount and the present value of the future cash flows at the asset(s) original effective interest rate.

If there is a favourable change in relation to the events surrounding the impairment loss then the impairment can be reviewed for possible reversal. The reversal will not cause the current carrying amount to exceed the original carrying amount had the impairment not been recognised. The impairment reversal is recognised in the profit or loss.

Basic financial liabilities

Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the Company after the deduction of all its liabilities.

Basic financial liabilities, which include trade and other creditors, bank loans and other loans are initially measured at their transaction price (adjusting for transaction costs except in the initial measurement of financial liabilities that are subsequently measured at fair value through profit and loss). When this constitutes a financing transaction, whereby the debt instrument is measured at the present value of the future payments discounted at a market rate of interest, discounting is omitted where the effect of discounting is immaterial.

Debt instruments are subsequently carried at their amortised cost using the effective interest rate method.

Trade creditors are obligations to pay for goods and services that have been acquired in the ordinary course of business from suppliers. Trade creditors are classified as current liabilities if the payment is due within one year. If not, they represent non-current liabilities. Trade creditors are initially recognised at their transaction price and subsequently are measured at amortised cost using the effective interest method. Discounting is omitted where the effect of discounting is immaterial.

Derecognition of financial instruments

Derecognition of financial assets

Financial assets are derecognised when their contractual right to future cash flow expire, or are settled, or when the Company transfers the asset and substantially all the risks and rewards of ownership to another party. If significant risks and rewards of ownership are retained after the transfer to another party, then the Company will continue to recognise the value of the portion of the risks and rewards retained.

 

Page 5

 
DR MANISH RAVAL LTD
 
 
 
Notes to the financial statements
For the year ended 30 November 2025

2.Accounting policies (continued)


2.7
Financial instruments (continued)

Derecognition of financial liabilities

Financial liabilities are derecognised when the Company's contractual obligations expire or are discharged or cancelled.

 
2.8

Creditors

Short-term creditors are measured at the transaction price. Other financial liabilities, including bank loans, are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method.

 
2.9

Provisions for liabilities

Provisions are recognised when an event has taken place that gives rise to a legal or constructive obligation, a transfer of economic benefits is probable and a reliable estimate can be made.

Provisions are measured as the best estimate of the amount required to settle the obligation, taking into account the related risks and uncertainties.
 
Increases in provisions are generally charged as an expense to profit or loss.

 
2.10

Current and deferred taxation

The tax expense for the year comprises current and deferred tax. Tax is recognised in profit or loss except that a charge attributable to an item of income and expense recognised as other comprehensive income or to an item recognised directly in equity is also recognised in other comprehensive income or directly in equity respectively.

The current income tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the balance sheet date in the countries where the Company operates and generates income.

Deferred tax balances are recognised in respect of all timing differences that have originated but not reversed by the balance sheet date, except that:
The recognition of deferred tax assets is limited to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits; and
Any deferred tax balances are reversed if and when all conditions for retaining associated tax allowances have been met.

Deferred tax balances are not recognised in respect of permanent differences except in respect of business combinations, when deferred tax is recognised on the differences between the fair values of assets acquired and the future tax deductions available for them and the differences between the fair values of liabilities acquired and the amount that will be assessed for tax. Deferred tax is determined using tax rates and laws that have been enacted or substantively enacted by the balance sheet date.


Page 6

 
DR MANISH RAVAL LTD
 
 
 
Notes to the financial statements
For the year ended 30 November 2025

3.


Employees

The average monthly number of employees, including directors, during the year was 2 (2024 - 2).


4.


Tangible fixed assets


Motor vehicles
Computer equipment
Total

£
£
£



Cost or valuation


At 1 December 2024
59,240
1,372
60,612


Additions
-
114
114



At 30 November 2025

59,240
1,486
60,726



Depreciation


At 1 December 2024
50,354
762
51,116


Charge for the year on owned assets
8,886
495
9,381



At 30 November 2025

59,240
1,257
60,497



Net book value



At 30 November 2025
-
229
229



At 30 November 2024
8,886
610
9,496


5.


Fixed asset investments





Listed investments

£



Cost or valuation


At 1 December 2024
1,366,717


Additions
718,057


Disposals
(601,119)


Revaluations
111,237



At 30 November 2025
1,594,892




Page 7

 
DR MANISH RAVAL LTD
 
 
 
Notes to the financial statements
For the year ended 30 November 2025

6.


Debtors

2025
2024
£
£


Trade debtors
31,008
21,935

Prepayments and accrued income
7,595
8,032

38,603
29,967



7.


Creditors: Amounts falling due within one year

2025
2024
£
£

Trade creditors
661
620

Corporation tax
92,657
79,486

Other creditors
2,690
2,599

Accruals and deferred income
11,367
10,500

107,375
93,205



8.


Deferred taxation




2025


£






At beginning of year
(47,356)


Charged to the profit or loss
(8,926)



At end of year
(56,282)

The provision for deferred taxation is made up as follows:

2025
2024
£
£


Accelerated capital allowances
(57)
(2,374)

Gain on investment in listed shares
(56,225)
(44,982)

(56,282)
(47,356)

Page 8

 
DR MANISH RAVAL LTD
 
 
 
Notes to the financial statements
For the year ended 30 November 2025

9.


Share capital

2025
2024
£
£
Allotted, called up and fully paid



200 (2024 - 200) Ordinary Shares shares of £1.00 each
200
200



10.


Pension commitments

The company operates a pension scheme on behalf of its employees. The assets of the scheme are held separately from those of the company in an independently administered fund.

The pension cost charge represents contributions payable by the company to the fund and amounted to £36,780 (2024: £24,750).

Contributions totalling £Nil (2024: £Nil) were payable to the fund at the balance sheet date.

 
Page 9